Any current/future new fundraising through debt or equity?

No specific refinancing initiatives have been undertaken yet; management considers it premature to discuss refinancing options at this stage. The company is open to refinancing but is currently focusing on sourcing funds at more attractive or cheaper costs. Recent capex has been funded through a mix of debt and internal accruals; peak debt may have been reached with near-commissioned projects. The company expects EBITDA growth from commissioned projects to improve leverage ratios despite elevated absolute debt levels. Future capex will be evaluated based on value accretiveness and marg

Any current/future capex/capital investment/strategic investment?

Current capex focuses on four key projects: - Aseptic packaging facility in Egypt (12 billion capacity, commissioning in H1 FY27) - WPP bag manufacturing unit in Mexico, targeting North America pet food market - PET recycling facility in India (commissioned in April FY26) - New BOPP packaging film manufacturing line in Dharwad, India (54,000 MTPA capacity, commissioning in FY27-28) Remaining capex to be capitalized in FY27 is around Rs. 1,900 - 2,000 crore, including Rs. 972 crore for aseptic facility and minor amounts for recycling. Post these projects, focus will be on incr

Future growth expectations in sales/revenue/volumes?

**Packaging business growth:** Expected to perform better in FY27 than FY26 due to improved utilization of recently commissioned capacities, product mix optimization, and new capacities coming online. **Aseptic packaging volumes:** Anticipated to increase from ~8 billion packs in FY26 to about 10.5 billion packs in FY27, including ramp-up of new capacity in Egypt. **Packaging films volumes:** Sequential recovery noted; however, FY26 volume declined 1%. Expect continued demand improvement but moderated by macroeconomic factors. **Regional growth:** Americas showed strong volume growth (23% Q-o-

Future growth expectations in earnings/operating earnings/profits/EPS?

Packaging Solutions business EBITDA contribution is expected to increase with new capacities commissioned, including aseptic packaging, WPP, and recycling segments (Page 19). The company projects aseptic packaging volumes to grow from 8 billion packs in FY26 to around 10.5 billion packs in FY27, factoring ramp-up in Egypt facility (Page 18). EBITDA margin improved by 70 bps YoY to 12.8% in FY26, with further margin expansion anticipated in Packaging Solutions due to higher value-added products (Page 10, 17). New projects in Egypt (aseptic packaging), Mexico (WPP bags), recycling, and Dharwad B

IN US

Sale is live|00:00:00left today

Uflex LtdQ1 FY26Industrial Products

Uflex Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹417P/E: 12.1Market Cap: ₹2.9K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→**Packaging business growth:** Expected to perform better in FY27 than FY26 due to improved utilization of recently commissioned capacities, product mix optimization, and new capacities coming online.
→**Aseptic packaging volumes:** Anticipated to increase from ~8 billion packs in FY26 to about 10.5 billion packs in FY27, including ramp-up of new capacity in Egypt.
→**Packaging films volumes:** Sequential recovery noted; however, FY26 volume declined 1%. Expect continued demand improvement but moderated by macroeconomic factors.
→**Regional growth:** Americas showed strong volume growth (23% Q-o-Q and 18% YoY) with improvements expected to continue.
→**Long-term prospects:** Supported by rising income levels, shifting consumer habits, accelerating urbanization, driving higher FMCG consumption and thus packaging demand.
→**EBITDA contribution:** Packaging Solutions (including aseptic) expected to increase its share from current ~40% to higher, indicating margin improvement.
→**Capex-driven growth:** New projects commissioning leading to increased revenues and volumes, e.g., BOPP line in Dharwad, aseptic facility in Egypt.

Margin guidance

Category 3

→Packaging Solutions business EBITDA contribution is expected to increase with new capacities commissioned, including aseptic packaging, WPP, and recycling segments (Page 19).
→The company projects aseptic packaging volumes to grow from 8 billion packs in FY26 to around 10.5 billion packs in FY27, factoring ramp-up in Egypt facility (Page 18).
→EBITDA margin improved by 70 bps YoY to 12.8% in FY26, with further margin expansion anticipated in Packaging Solutions due to higher value-added products (Page 10, 17).
→New projects in Egypt (aseptic packaging), Mexico (WPP bags), recycling, and Dharwad BOPP lines are expected to contribute significant EBITDA from FY27 onwards (Page 9, 15).
→Operating leverage from recently commissioned facilities, product mix optimization, and higher utilization are key drivers for improved profits and EPS in FY27 and beyond (Page 6, 18).
→Management remains optimistic about long-term growth, facilitated by rising income, urbanization, and consumption trends in key markets (Page 6).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No specific refinancing initiatives have been undertaken yet; management considers it premature to discuss refinancing options at this stage.
→The company is open to refinancing but is currently focusing on sourcing funds at more attractive or cheaper costs.
→Recent capex has been funded through a mix of debt and internal accruals; peak debt may have been reached with near-commissioned projects.
→The company expects EBITDA growth from commissioned projects to improve leverage ratios despite elevated absolute debt levels.
→Future capex will be evaluated based on value accretiveness and margin expansion opportunities; no concrete plans for new fundraises via equity or debt were mentioned.
→Overall blended cost of funds currently stands at approximately 9%.

Order book

The transcript provided does not mention any specific details about the current or expected order book or pending orders for UFlex Limited. The discussion primarily focuses on: - Capacity utilization and expansion plans (e.g., aseptic packaging capacity in India and Egypt). - Capex projects and their commissioning timelines. - EBITDA margins and financial performance trends. - Market dynamics in various product segments and regions. - Cost of debt and leverage ratios. - Growth prospects and strategy across packaging segments. No direct reference or quantitative information about order book status or pending orders is provided in the earnings call transcript.

Capex plans

Yes

→Current capex focuses on four key projects:
→ - Aseptic packaging facility in Egypt (12 billion capacity, commissioning in H1 FY27)
→ - WPP bag manufacturing unit in Mexico, targeting North America pet food market
→ - PET recycling facility in India (commissioned in April FY26)
→ - New BOPP packaging film manufacturing line in Dharwad, India (54,000 MTPA capacity, commissioning in FY27-28)
→Remaining capex to be capitalized in FY27 is around Rs. 1,900 - 2,000 crore, including Rs. 972 crore for aseptic facility and minor amounts for recycling.
→Post these projects, focus will be on increasing asset utilization and optimizing capex to ensure EBITDA growth.
→Open to new value-accretive capex globally with high margin potential and right product mix.
→Current phase is near the peak debt and commissioning; next phase expected to be sweating the assets with improved utilization.

How does Uflex Ltd rank vs peers in Industrial Products?

Pro feature

1Uflex Ltd

Rev 3Mar 3

See full Industrial Products sector rankings

Want more stocks like Uflex Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio